Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES F LOVELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174629448
CMS profile
325880
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,516.90

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,705.48 10
Food and Beverage $1,811.42 54

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES F LOVELL

NPI 1174629448 · CMS profile ID 325880

Allopathic & Osteopathic Physicians / Internal Medicine

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $4,516.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk AS $836.8112/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543313 CMS
Novo Nordisk AS $193.5512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543315 CMS
Novo Nordisk AS $159.1112/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543317 CMS
Novo Nordisk AS $14.5012/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543319 CMS
Novo Nordisk AS $274.8312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544629 CMS
Novo Nordisk AS $29.7512/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544631 CMS
ARBOR PHARMACEUTICALS, INC. $13.2212/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697363761 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.8011/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384883 CMS
Novo Nordisk Inc $13.8610/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690073957 CMS
Janssen Pharmaceuticals, Inc $79.1110/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939461 CMS
Novartis Pharmaceuticals Corporation $17.5310/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574319 CMS
ARBOR PHARMACEUTICALS, INC. $11.7009/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697363757 CMS
AstraZeneca Pharmaceuticals LP $24.8309/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685407031 CMS
SANOFI-AVENTIS U.S. LLC $20.3909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694155873 CMS
Janssen Pharmaceuticals, Inc $2.5109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939457 CMS
Novo Nordisk AS $466.6009/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543153 CMS
Novo Nordisk AS $166.1409/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543155 CMS
Novo Nordisk AS $92.7109/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543157 CMS
Novo Nordisk AS $222.6209/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544565 CMS
Novartis Pharmaceuticals Corporation $18.2709/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574317 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.8609/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753385673 CMS
LivaNova USA, Inc. $24.7009/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703467409 CMS
Amgen Inc. $20.8908/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662244203 CMS
Janssen Pharmaceuticals, Inc $2.5108/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939453 CMS
Novo Nordisk Inc $11.0308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674610519 CMS
Amgen Inc. $20.0508/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662244207 CMS
Merck Sharp & Dohme Corporation $10.9907/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695675179 CMS
PFIZER INC. $17.0707/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672360719 CMS
Novo Nordisk Inc $3.7407/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682744493 CMS
Novartis Pharmaceuticals Corporation $19.8807/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574321 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1607/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384885 CMS
Janssen Pharmaceuticals, Inc $10.1707/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939445 CMS
Janssen Pharmaceuticals, Inc $3.9706/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939443 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $0.4106/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384887 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.9506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384889 CMS
Radius Health, Inc. $27.2506/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683953537 CMS
Novo Nordisk Inc $11.4106/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674464105 CMS
Novo Nordisk Inc $38.5005/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690073955 CMS
Novo Nordisk AS $311.0905/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543135 CMS
Novo Nordisk AS $224.8705/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543137 CMS
Novo Nordisk AS $240.1005/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543139 CMS
Novo Nordisk AS $350.0005/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544559 CMS
Novartis Pharmaceuticals Corporation $14.5005/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574315 CMS
Novo Nordisk Inc $11.7905/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669566009 CMS
Amarin Pharma Inc. $21.1705/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699141161 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $4.4705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384891 CMS
Janssen Pharmaceuticals, Inc $10.6204/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939435 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $99.1403/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700445695 CMS
Novartis Pharmaceuticals Corporation $21.0603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574311 CMS
Strongbridge US INC. $11.3703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688229651 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,516.90 64
PY2020 $2,823.11 39
PY2021 $2,590.74 45
PY2022 $737.64 35
PY2023 $454.03 20
PY2024 $2,529.63 39
PY2025 $681.28 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,318.22 41
PY2024 Principal investigator $226,779.68 27
PY2023 Principal investigator $241,422.11 79
PY2022 Principal investigator $283,192.02 266
PY2021 Principal investigator $197,651.91 425
PY2020 Principal investigator $248,697.42 325
PY2019 Recipient $12,988.10 1
PY2019 Principal investigator $359,002.06 260

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $29.00 12/31/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096840711
Principal investigator 1 Novo Nordisk AS $29.00 11/29/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096860579
Principal investigator 1 Novo Nordisk AS $29.00 10/31/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096726373
Principal investigator 1 Novo Nordisk AS $29.00 09/30/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096864152
Principal investigator 1 Novo Nordisk AS $29.00 08/30/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096775681
Principal investigator 1 AstraZeneca Pharmaceuticals LP $67,482.25 08/28/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Phase IIb Multicenter Randomised DoubleBlind Dose-inding Study to Evaluate the Efficacy Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria No dispute reported 06/30/2026 1110836830
Principal investigator 1 ModernaTX, Inc. $957.96 08/28/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147186415
Principal investigator 1 ModernaTX, Inc. $1,111.00 08/14/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147186413
Principal investigator 1 Novo Nordisk AS $29.00 07/31/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096841256
Principal investigator 1 ModernaTX, Inc. $1,109.16 07/17/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147186369
Principal investigator 1 ModernaTX, Inc. $10,411.20 07/05/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147186371
Principal investigator 1 Novo Nordisk AS $29.00 06/28/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096761595
Principal investigator 1 ModernaTX, Inc. $1,053.96 06/21/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147186359
Principal investigator 1 Novo Nordisk AS $11,670.83 06/14/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1096809187
Principal investigator 1 Novo Nordisk AS $2,750.00 06/14/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1096817133
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,877.87 06/07/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110837876
Principal investigator 1 ModernaTX, Inc. $6,705.72 06/07/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147186357
Principal investigator 1 Novo Nordisk AS $29.00 05/31/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096763066
Principal investigator 1 Novo Nordisk AS $29.00 04/30/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096819492
Principal investigator 1 Novo Nordisk AS $29.00 03/29/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096787283
Principal investigator 1 Novo Nordisk AS $29.00 02/29/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096880743
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,472.00 01/31/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1089687131
Principal investigator 1 Novo Nordisk AS $29.00 01/31/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1096749415
Principal investigator 1 Novartis Pharmaceuticals Corporation $50,529.68 01/30/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1089687513
Principal investigator 1 Novo Nordisk AS $4,106.57 01/29/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1096857311
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,641.94 01/15/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1089686749
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $17,551.54 01/01/2024 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1095481664